Sanjiv.Parant.

- Total capex for Hindustan Antibiotic Limited (HAL) JV: INR 35-38 crores; 10% invested so far; 70% of major equipment ordered; plant layout finalizing; civil work to start soon; revenue expected from Q4 FY25. - Prague facility capex: INR 3 to 3.5 crores already spent; includes packaging line delayed to late March due to Red Sea embargo; targeting entry into European and American markets. - Current facility upgrades (Dehradun and Mumbai): INR 4-5 crores planned; includes regulatory approvals and capacity enhancements. - Financing through preference shares and internal accruals; working with HR firm to expand senior management in line with fundraising. - Strategic investments to access regulated and semi-regulated markets, expanding product portfolio and market presence.

- The company is poised to report good results and revenues in the coming years, supported by strong tie-ups and good market access. - Dehradun facility upgradation is underway, with upcoming inspections expected to enable approvals in multiple Latin American countries and potentially East European countries by end of 2024, expanding market reach. - Focus on expanding export markets, especially in Latin America, Francophone Africa, and East Africa, targeting new countries for growth. - Management team expansion with addition of 15-20 senior management personnel will support scaling operations. - Continued product portfolio expansion with 15-20 new products annually, adding to injectables and orals, primarily targeting chronic diseases. - Capacity utilization is growing, with injectables at 70% and orals at 35%, and an expectation of sustained growth in injectables. - Government tenders and private markets are competitive, with some regions having stable or growing market share. - The company aims to maintain a 75% export and 25% domestic revenue mix.

- The company is poised to report good results and revenues in the coming years due to strong tie-ups and good market access. - Expansion plans include plant upgrades (notably Dehradun) and a new HAL facility expected to be operational from October 2024. - New senior management hiring underway to support growth. - Injection segment showing rapid growth with increased demand from new geographies. - The planned revenue mix is targeted at maintaining 75% export and 25% domestic sales. - Addition of 15-20 new senior management personnel is expected, supporting scaling operations. - Ongoing expansions into Latin America, Francophone Africa, and East European countries. - Company expects margins to normalize post initial contraction from new products. - Long-term aspirational revenue targets for FY27 and FY28 were queried but specific numbers were not disclosed.

- The transcript does not explicitly mention specific current or expected orderbook or pending orders figures. - However, Ashwani Khemka mentions good tie-ups and good market access, implying a healthy order pipeline. - There is a focus on increased demand, especially from newer geographies in the injectables segment. - The company expects good revenues and results going forward, supported by ongoing plant upgrades and approvals. - The HAL project is progressing as planned with machinery ordered and site activities beginning, suggesting future order fulfillment capacity increase. - They mention efforts to expand export markets (Latin America, Francophone Africa, East European countries), which may contribute to future order growth. - Product additions and regulatory approvals aim to drive growth, further indirectly pointing to an expected growing orderbook. No specific quantitative figures for orders were disclosed in the provided transcript.

- The transcript does not explicitly mention any current or planned fundraising through debt or equity. - However, it mentions company expansion plans including management team growth and plant upgrades. - Ashwani Khemka mentioned expansion of the management team in light of a "fundraiser," indicating some form of capital raising is planned or ongoing, but details such as amount, type (debt/equity), or timing are not provided. - The company is investing in new facilities such as the Hindustan Antibiotic JV with a total capex of around INR 35 to 38 crores, with about 10% spent so far. - No specific fundraising details like amounts or instruments were disclosed in this call transcript.